HRP20191550T1 - Derivati imidazopiridazina kao inhibitori pi3kbeta - Google Patents
Derivati imidazopiridazina kao inhibitori pi3kbeta Download PDFInfo
- Publication number
- HRP20191550T1 HRP20191550T1 HRP20191550T HRP20191550T1 HR P20191550 T1 HRP20191550 T1 HR P20191550T1 HR P20191550 T HRP20191550 T HR P20191550T HR P20191550 T1 HRP20191550 T1 HR P20191550T1
- Authority
- HR
- Croatia
- Prior art keywords
- 4alkyl
- substituents
- substituted
- alkyl
- hydrogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Gynecology & Obstetrics (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Pregnancy & Childbirth (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Taps Or Cocks (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14199322 | 2014-12-19 | ||
| EP15810784.7A EP3233862B1 (en) | 2014-12-19 | 2015-12-18 | Imidazopyridazine derivatives as pi3kbeta inhibitors |
| PCT/EP2015/080604 WO2016097347A1 (en) | 2014-12-19 | 2015-12-18 | IMIDAZOPYRIDAZINE DERIVATIVES AS ΡΙ3Κβ INHIBITORS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20191550T1 true HRP20191550T1 (hr) | 2019-11-29 |
Family
ID=52134002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20191550 HRP20191550T1 (hr) | 2014-12-19 | 2015-12-18 | Derivati imidazopiridazina kao inhibitori pi3kbeta |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US10087187B2 (https=) |
| EP (1) | EP3233862B1 (https=) |
| JP (1) | JP6568588B2 (https=) |
| KR (1) | KR20170095239A (https=) |
| CN (1) | CN107108634B (https=) |
| AU (1) | AU2015366190B2 (https=) |
| BR (1) | BR112017012930A2 (https=) |
| CA (1) | CA2967551A1 (https=) |
| CY (1) | CY1122381T1 (https=) |
| DK (1) | DK3233862T3 (https=) |
| EA (1) | EA029789B1 (https=) |
| ES (1) | ES2761051T3 (https=) |
| HR (1) | HRP20191550T1 (https=) |
| HU (1) | HUE045220T2 (https=) |
| IL (1) | IL252866B (https=) |
| LT (1) | LT3233862T (https=) |
| MA (1) | MA41174B1 (https=) |
| MD (1) | MD3233862T2 (https=) |
| ME (1) | ME03517B (https=) |
| MX (1) | MX2017008074A (https=) |
| PL (1) | PL3233862T3 (https=) |
| PT (1) | PT3233862T (https=) |
| RS (1) | RS59301B1 (https=) |
| SI (1) | SI3233862T1 (https=) |
| SM (1) | SMT201900509T1 (https=) |
| WO (1) | WO2016097347A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10526316B2 (en) | 2015-10-09 | 2020-01-07 | Janssen Pharmaceutica Nv | Quinoxaline and pyridopyrazine derivatives as PI3Kβ inhibitors |
| DK3472160T3 (da) | 2016-06-16 | 2021-05-10 | Janssen Pharmaceutica Nv | Bicykliske pyridin-, pyrazin- og pyrimidinderivater som pi3k-beta-inhibitorer |
| EP3601254B1 (en) | 2017-03-29 | 2022-05-25 | Janssen Pharmaceutica NV | Quinoxaline and pyridopyrazine derivatives as pi3k-beta inhibitors |
| JP7637328B2 (ja) | 2019-02-07 | 2025-02-28 | ベイジーン リミテッド | Ｔｌｒ７アゴニストとしてのイミダゾ［２，１－ｆ］［１，２，４］トリアジン－４－アミン誘導体 |
| CN110128505A (zh) * | 2019-05-21 | 2019-08-16 | 梯尔希（南京）药物研发有限公司 | 一种戈舍瑞林杂质的合成方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070078136A1 (en) | 2005-09-22 | 2007-04-05 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| PE20080403A1 (es) | 2006-07-14 | 2008-04-25 | Amgen Inc | Derivados heterociclicos fusionados y metodos de uso |
| US8217177B2 (en) | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| WO2008014219A2 (en) | 2006-07-24 | 2008-01-31 | Smithkline Beecham Corporation | Thiozolidinedione derivatives as p13 kinase inhibitors |
| CA2663091A1 (en) | 2006-09-07 | 2008-03-13 | Biogen Idec Ma Inc. | Modulators of interleukin-1 receptor-associated kinase |
| CA2684932A1 (en) * | 2007-05-09 | 2008-11-20 | Novartis Ag | Substituted imidazopyridazines as pi3k lipid kinase inhibitors |
| EP2217601A1 (en) * | 2007-11-08 | 2010-08-18 | Centro Nacional de Investigaciones Oncológicas (CNIO) | Imidazopyridazines for use as protein kinase inhibitors |
| PE20091468A1 (es) * | 2008-02-28 | 2009-10-22 | Novartis Ag | DERIVADOS DE 3-METIL-IMIDAZO-[1,2-b]-PIRIDAZINA |
| WO2010007099A1 (en) | 2008-07-15 | 2010-01-21 | Cellzome Limited | 2-aminoimidazo[1,2-b]pyridazine derivatives as pi3k inhibitors |
| PE20121148A1 (es) | 2009-08-17 | 2012-09-07 | Intellikine Llc | Compuestos heterociclicos y usos de los mismos |
| DE102009049679A1 (de) * | 2009-10-19 | 2011-04-21 | Merck Patent Gmbh | Pyrazolopyrimidinderivate |
| WO2011058109A1 (en) | 2009-11-12 | 2011-05-19 | Ucb Pharma S.A. | Fused bicyclic pyrrole and imidazole derivatives as kinase inhibitors |
| UY33304A (es) | 2010-04-02 | 2011-10-31 | Amgen Inc | Compuestos heterocíclicos y sus usos |
| JP5719028B2 (ja) | 2010-10-06 | 2015-05-13 | グラクソスミスクライン エルエルシー | Ｐｉ３キナーゼ阻害剤としてのベンズイミダゾール誘導体 |
| WO2012116237A2 (en) | 2011-02-23 | 2012-08-30 | Intellikine, Llc | Heterocyclic compounds and uses thereof |
| WO2013028263A1 (en) * | 2011-08-24 | 2013-02-28 | Glaxosmithkline Llc | Pyrazolopyrimidine derivatives as pi3 kinase inhibitors |
| WO2013095761A1 (en) * | 2011-12-20 | 2013-06-27 | Glaxosmithkline Llc | Imidazopyridine derivatives as pi3 kinase inhibitors |
| US8778937B2 (en) | 2011-12-20 | 2014-07-15 | Glaxosmithkline Llc | Benzimidazole boronic acid derivatives as PI3 kinase inhibitors |
| TWI574962B (zh) | 2012-11-14 | 2017-03-21 | 加拓科學公司 | 作爲ｐｉ３激酶調節劑的芳雜環化合物及其使用方法和用途 |
| GB201321734D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
-
2015
- 2015-12-18 MA MA41174A patent/MA41174B1/fr unknown
- 2015-12-18 ES ES15810784T patent/ES2761051T3/es active Active
- 2015-12-18 JP JP2017532819A patent/JP6568588B2/ja not_active Expired - Fee Related
- 2015-12-18 EP EP15810784.7A patent/EP3233862B1/en active Active
- 2015-12-18 RS RSP20191225 patent/RS59301B1/sr unknown
- 2015-12-18 BR BR112017012930A patent/BR112017012930A2/pt active Search and Examination
- 2015-12-18 AU AU2015366190A patent/AU2015366190B2/en not_active Ceased
- 2015-12-18 HR HRP20191550 patent/HRP20191550T1/hr unknown
- 2015-12-18 DK DK15810784.7T patent/DK3233862T3/da active
- 2015-12-18 PT PT158107847T patent/PT3233862T/pt unknown
- 2015-12-18 HU HUE15810784A patent/HUE045220T2/hu unknown
- 2015-12-18 WO PCT/EP2015/080604 patent/WO2016097347A1/en not_active Ceased
- 2015-12-18 MX MX2017008074A patent/MX2017008074A/es active IP Right Grant
- 2015-12-18 CA CA2967551A patent/CA2967551A1/en active Pending
- 2015-12-18 SM SM20190509T patent/SMT201900509T1/it unknown
- 2015-12-18 US US15/537,551 patent/US10087187B2/en active Active
- 2015-12-18 CN CN201580069133.7A patent/CN107108634B/zh not_active Expired - Fee Related
- 2015-12-18 LT LTEP15810784.7T patent/LT3233862T/lt unknown
- 2015-12-18 SI SI201530855T patent/SI3233862T1/sl unknown
- 2015-12-18 MD MDE20170191 patent/MD3233862T2/ro not_active IP Right Cessation
- 2015-12-18 ME MEP-2019-263A patent/ME03517B/me unknown
- 2015-12-18 KR KR1020177016722A patent/KR20170095239A/ko not_active Ceased
- 2015-12-18 EA EA201791396A patent/EA029789B1/ru not_active IP Right Cessation
- 2015-12-18 PL PL15810784T patent/PL3233862T3/pl unknown
-
2017
- 2017-06-13 IL IL252866A patent/IL252866B/en active IP Right Grant
-
2019
- 2019-10-03 CY CY20191101031T patent/CY1122381T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN107108634B (zh) | 2020-09-15 |
| MA41174B1 (fr) | 2019-09-30 |
| SI3233862T1 (sl) | 2019-09-30 |
| AU2015366190B2 (en) | 2020-01-23 |
| EA201791396A1 (ru) | 2017-10-31 |
| PT3233862T (pt) | 2019-10-09 |
| US10087187B2 (en) | 2018-10-02 |
| EA029789B1 (ru) | 2018-05-31 |
| HUE045220T2 (hu) | 2019-12-30 |
| US20180002336A1 (en) | 2018-01-04 |
| CN107108634A (zh) | 2017-08-29 |
| MX2017008074A (es) | 2018-01-09 |
| EP3233862A1 (en) | 2017-10-25 |
| IL252866A0 (en) | 2017-08-31 |
| SMT201900509T1 (it) | 2019-11-13 |
| JP2017538734A (ja) | 2017-12-28 |
| RS59301B1 (sr) | 2019-10-31 |
| WO2016097347A1 (en) | 2016-06-23 |
| BR112017012930A2 (pt) | 2018-01-09 |
| CY1122381T1 (el) | 2021-01-27 |
| MA41174A (fr) | 2017-10-25 |
| ES2761051T3 (es) | 2020-05-18 |
| DK3233862T3 (da) | 2019-10-07 |
| MD3233862T2 (ro) | 2019-11-30 |
| IL252866B (en) | 2020-09-30 |
| CA2967551A1 (en) | 2016-06-23 |
| KR20170095239A (ko) | 2017-08-22 |
| ME03517B (me) | 2020-04-20 |
| JP6568588B2 (ja) | 2019-08-28 |
| AU2015366190A1 (en) | 2017-05-25 |
| LT3233862T (lt) | 2019-09-10 |
| EP3233862B1 (en) | 2019-07-03 |
| PL3233862T3 (pl) | 2020-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201891049A1 (ru) | Изоиндолиновые, азаизоиндолиновые, дигидроинденоновые и дигидроазаинденоновые ингибиторы mnk1 и mnk2 | |
| HRP20191550T1 (hr) | Derivati imidazopiridazina kao inhibitori pi3kbeta | |
| MX2017007748A (es) | Compuestos de heteroarilo anulares fusionados y su uso como inhibidores del receptor de la tirocina cinasa (trk). | |
| TR201904455T4 (tr) | Nükleer taşıma modülatörleri olarak 1,2,4-triazoller ve bunların kullanımları. | |
| ZA201903161B (en) | Antiviral compositions for the treatment of infections linked to coronaviruses | |
| CU24350B1 (es) | DERIVADOS DE 5-HETEROARIL-4-FENIL-4,5-DIHIDROPIRROLO(3,4-c)PIRAZOL-6-ONA ACTIVOS COMO INHIBIDORES DE BET | |
| WO2017205536A3 (en) | Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer | |
| BR112015021983A8 (pt) | compostos heterocíclicos, composições e usos dos mesmos | |
| UY36112A (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer | |
| BR112015022643A2 (pt) | inibidores diidro-pirrolpiridinona | |
| BR112015028501A2 (pt) | derivados de bipirazol como inibidores de jak | |
| UY35573A (es) | Derivados de sulfamoilpirrolamida y su uso como m edicamentos para el tratamiento de la hepatitis b | |
| MD4666B1 (ro) | Inhibitori ai Syk | |
| EA201891050A1 (ru) | Соединения пирроло-, пиразоло-, имидазопиримидина и пиридина, которые ингибируют mnk1 и mnk2 | |
| MX2019012847A (es) | Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer. | |
| AR097199A1 (es) | Inhibidores de rorc2 y sus métodos de uso | |
| BR112015017929A2 (pt) | di-hidropirimidinonas bicíclicas substituídas e seu uso como inibidores de atividade elastase neutrófila | |
| UY36145A (es) | Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer | |
| EA201690888A1 (ru) | Новые гетероциклические соединения | |
| MX2016007440A (es) | Inhibidores del bromodominio. | |
| MX2016004114A (es) | Derivados de 1,4-dihidrodioxina fusionada como inhibidores del factor de trascripcion de choque termico 1. | |
| GEAP202215599A (en) | Boron containing pde4 inhibitors | |
| JP2018535199A5 (https=) | ||
| EA201790276A1 (ru) | Новые имидазопиридазиновые соединения и их применение | |
| ZA201607489B (en) | Combination comprising a glucocorticoid and edo-s101 |